| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
Form 4: Quigley Jill M., Director
Granted 53,000 Stock Option (Right to Buy) |
| 12 Nov 2026 | Form 3 |
| 12 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
–Appointment brings leadership experience building and financing biopharma companies |
| 05 Nov 2026 | FORM 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
– Patient screening in Phase 2a study of simufilam in TSC-related epilepsy expected to begin by Q1 2027, following recent lift of FDA clinical hold |
| 20 Oct 2026 |
8-K: Other Events
On October 16, 2026, the United States Court of Appeals for the Fifth Circuit (the “Fifth Circuit”) vacated the order of the U.S. District Court for the Western District of Texas (the “Texas District Court”) granting class certification ... |
| 01 Oct 2026 |
Form 4: Barry Richard, Director
Bought 206,813 shares ($186K) · Bought 100,000 shares ($92K) |
| 30 Sep 2026 |
Form 4: Barry Richard, Director
Bought 93,091 shares ($78.2K) |
| 22 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
AUSTIN, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis C... |
| 18 Sep 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 29 Jul 2026 | FORM 10-Q |
| 29 Jul 2026 |
8-K: Results of Operations and Financial Condition
AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-relat... |
| 15 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company’s business. |
| 07 May 2026 | FORM 10-Q |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-relate... |
| 28 Apr 2026 | FORM ARS |
| 28 Apr 2026 |
Proxy statement: annual meeting on June 11, 2026
CEO pay $1.5M, down 91% · say-on-pay vote |
| 28 Apr 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 12 Mar 2026 | FORM 10-K |
| 12 Mar 2026 |
8-K: Results of Operations and Financial Condition
AUSTIN, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company focused on developing novel medicines to modulate... |
Loading...